Boston Scientific weathered ongoing COVID-19 and macroeconomic pressures in the second quarter, leading the company to raise its 2022 forecast for organic revenue growth.
CEO Michael Mahoney said on a Wednesday earnings call that the company now expects more “durable and consistent procedural growth” for the remainder of 2022. “We had just tremendous growth in each region,” Mahoney said.
The CEO specifically called out China, where the company grew sales by 9% despite the country implementing lockdowns due to rising COVID-19 cases. Boston Scientific still expects the region to grow sales by double digits this year.
